Defining pharmacist's role in optimizing prescription digital therapeutics for patients with schizophrenia: A modified Delphi consensus perspective
Open Access
- 1 October 2026
- journal article
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 67 (1) , 103537
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
This publication has 45 references indexed in Scilit:
- A comprehensive survey of the clinical trial Landscape on digital therapeuticsHeliyon, 2024
- Schizophrenia and medication adherence: Associated factorsArchives of Psychiatric Nursing, 2024
- Prescription digital therapeutics: A new frontier for pharmacists and the future of treatmentJournal of the American Pharmacists Association, 2023
- Digital transformation of healthcare sector. What is impeding adoption and continued usage of technology-driven innovations by end-users?Journal of Business Research, 2022
- Growing the Psychiatry Workforce Through Expansion or Creation of Residencies and Fellowships: the Results of a Survey by the AADPRT Workforce Task ForceAcademic Psychiatry, 2021
- Preparing, conducting, and analyzing Delphi surveys: Cross-disciplinary practices, new directions, and advancementsMethodsX, 2021
- Digital Technologies for Schizophrenia Management: A Descriptive ReviewScience and Engineering Ethics, 2021
- Evaluating the Impact of Freespira on Panic Disorder Patients’ Health Outcomes and Healthcare Costs within the Allegheny Health NetworkApplied Psychophysiology and Biofeedback, 2020
- Stepped Care as an Implementation and Service Delivery Model for Cognitive Behavioral Therapy for PsychosisCommunity Mental Health Journal, 2019
- Geographic Variation in the Supply of Selected Behavioral Health ProvidersAmerican Journal of Preventive Medicine, 2018